Company Encyclopedia
View More
name
Lonza
O6Z.SG
Lonza Group AG is engaged in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment offers small molecule drug substances and intermediates related services. The Cell and Gene segment includes the Cell and Gene Technologies and Bioscience businesses. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.
--
O6Z.SGMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | Lonza continuously suppresses near the turning point, will the main force's unusual movements unfold?

    Lonza has frequently tested the bottom line of 65.03 in recent trading days, with a decrease in volume and a pullback. The CRO sector is generally weak, and various speculative funds have basically exited to observe. The community is hotly discussing whether the main force is accumulating strength to find a bottom, or if some are waiting for news-driven fluctuations to hunt for a rebound. All indicators in the technical circle are hovering at low levels, with volume continuously shrinking, and there is no willingness to push up during each tug-of-war. Short-term traders prefer to wait for situations where "suddenly large orders are dumped in, or industry mergers happen overnight," as a surge in volume can directly ignite sector sentiment. Practitioners pay more attention to intraday volume, market support actions, and the layout of main funds. Today's biggest opportunity hinges on whether 65.03 can hold; if a main force assault signal appears, there is a high probability of an intraday rebound opportunity. Otherwise, continuing to grind at the bottom may easily drag one into a liquidity black hole. It is recommended to closely monitor news and new market movements, and to follow up on short-term trades as soon as there is any fluctuation, while being firm on stop-losses if the bottom line breaks

    Technical Forecast·
    Technical Forecast·

    Morning Trend | Lonza stabilizes with reduced volume, can it welcome capital inflow after a pullback?

    Lonza (LZAGY.US) recently halted its consecutive decline, with a decrease in volume yesterday marking a stabilization. The K-line has initially formed a bottom structure, and the market's bullish sentiment is gradually rising. Funds are shifting from a wait-and-see approach to being more active, with community discussions focusing on "whether funds will flow back in large quantities after a pullback," and the sentiment for buying on dips is noticeably warming up. On the news front, the company has completed significant international mergers and acquisitions, and the prosperity of the life sciences sector continues to improve, returning to the growth mainline. Recent earnings guidance is relatively optimistic, and some institutions are increasing their positions at lower levels in anticipation of a rebound. Affected by market fluctuations, the trading volume has not truly increased yet, but after a series of declines, the technical basis for a rebound has been solidified. The short-term risk mainly lies in whether the selling pressure is fully released; if the volume can break through the bottom neckline during trading, a new round of funds is expected to enter in large quantities. If the volume continues to be low and the stock trades sideways, the height of the rebound may be limited. The operational suggestion is to closely observe fund dynamics around the "low-volume stabilization" structure, pay attention to the synergistic driving effect of the global biotechnology sector, and effectively combine chasing gains with risk control during pullbacks

    Technical Forecast·
    Technical Forecast·